PNKP and neoplasm: Nevertheless, a sustained inhibition of PNKP resulting from higher accumulation of its nano-formulation in tumor xenografts along with a continuous release of the drug in the tumor site might have been responsible for the higher activity of NP/A83 over CE/A83, in vivo.